'Real‐World' Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States

Autor: Won Chan Lee, Hsiao D. Lieu, Mark B. Effron, Jingsong Lu, Yajun Zhu, Mitch DeKoven, Swapna Karkare, Cynthia Larmore, Cliff Molife, George W. Vetrovec
Rok vydání: 2015
Předmět:
Male
Ticagrelor
Adenosine
Time Factors
Prasugrel
Databases
Factual
medicine.medical_treatment
Comorbidity
030204 cardiovascular system & hematology
law.invention
0302 clinical medicine
Randomized controlled trial
Risk Factors
law
Odds Ratio
030212 general & internal medicine
Myocardial infarction
Practice Patterns
Physicians'
Age Factors
General Medicine
Middle Aged
Clopidogrel
Hospitalization
Treatment Outcome
Cardiology
Female
Cardiology and Cardiovascular Medicine
medicine.drug
Acute coronary syndrome
medicine.medical_specialty
Hemorrhage
03 medical and health sciences
Percutaneous Coronary Intervention
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Acute Coronary Syndrome
Propensity Score
Aged
Retrospective Studies
Chi-Square Distribution
business.industry
Percutaneous coronary intervention
medicine.disease
United States
business
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors
Mace
Zdroj: Catheterization and Cardiovascular Interventions. 88:535-544
ISSN: 1522-726X
1522-1946
Popis: Objectives: The 30-day clinical outcomes with prasugrel or ticagrelor were comparedusing a US payer database in patients with acute coronary syndrome (ACS) undergoingpercutaneous coronary intervention (PCI).Background: Prasugrel and ticagrelor dem-onstrated superior efficacy with increased non-coronary artery bypass graft majorbleeding compared with clopidogrel in randomized clinical trials. No direct randomizedor observational studies have compared clinical outcomes between prasugrel and tica-grelor.Methods: Patients hospitalized for ACS-PCI between August 1, 2011 and April30, 2013 and prescribed prasugrel or ticagrelor were selected. Drug treatment cohortswere propensity matched based upon demographic and clinical characteristics. Theprimary objective compared 30-day net adverse clinical events (NACE) in prasugrel-and ticagrelor-treated patients using a prespecified 20% noninferiority margin. Second-ary objectives included comparisons of major adverse cardiovascular events (MACE)and major bleeding.Results: Data were available for 16,098 patients (prasugrel,n513,134; ticagrelor,n52,964). In unmatched cohorts, prasugrel-treated patients wereyounger with fewer comorbidities than ticagrelor-treated patients, and 30-day NACE rateswere 5.6 and 9.3%, respectively (P
Databáze: OpenAIRE
Externí odkaz: